Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use.

Expert review of clinical pharmacology - 1 Jan 2026

Thuy Han Minh, Sugimoto Mitsushige, Quang Pham Minh Ngoc, Yamaoka Yoshio

Abstract excerpt

INTRODUCTION: Proton pump inhibitors (PPIs) are widely used to treat acid-related disorders; however, treatment response varies significantly due to Cytochrome P450 2C19 (CYP2C19) genetic polymorphisms that alter individual drug metabolism. Such variation can lead to insufficient acid suppression, resulting in treatment failure or adverse events. Genotype-guided PPI therapy represents an important step toward...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C19
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gastroesophageal Reflux

Share to Helicobacter Infections

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Precision Medicine

Share to Proton Pump Inhibitors

Source

Identifiers

PMID: 41618926
DOI: 10.1080/17512433.2026.2626454

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use.PMID 41618926Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Semantic proximity Read ↗

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Semantic proximity Read ↗

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.Semantic proximity Read ↗

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Semantic proximity Read ↗

New Guidance on Cytochrome P450 2C19 Phenotype-based Use of Proton Pump Inhibitors.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.Semantic proximity Read ↗

Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.Semantic proximity Read ↗

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.Semantic proximity Read ↗

New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors.Semantic proximity Read ↗

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Semantic proximity Read ↗

Association of CYP2C19 Phenotype on Historical Medication Prescribing for Gastroesophageal Reflux Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.